Nondestructive focused ultrasound coronary artery in-vitro thrombus dissolving system

Abstract

The invention discloses a stereotactic, multifrequency and nondestructive focused ultrasound coronary artery in-vitro thrombus dissolving system, which is characterized in that: a positioning metal breast band is worn for performing image study and acquiring positioning image data; a medical image three-dimensional reconstruction technique is used to determine a lesion site and a treatment position; a multidimensional low-power and low-frequency ultrasonic transducer is placed on the same cut face of a coronary artery thrombosis lesion to form a stable ultrasonic cavitation effect in a thrombus or thrombosis lesion; a medium and / or high-frequency focused ultrasound transducer is used to irradiate the thrombus by a focused ultrasonic wave focal spot from a position of the same cut face of body surface which is most close to the thrombosis lesion; focused ultrasonic waves are focused with high power, high sound intensity and high accuracy and intermittently emitted in a pulse modulated ultrasonic wave mode in a short time to form instant instable ultrasonic wave cavitation effect in the thrombus to induce internal blasting in the thrombus, so that the thrombus disintegrates and dissolves quickly; and while the thrombus dissolves quickly and effectively, the inner walls of the blood vessels and normal cardiac muscular tissues around are not damaged, and an in-vitro nondestructive thrombus dissolving effect is achieved.

Description

technical field [0001] The invention relates to the technical field of medical devices, in particular to a stereotactic, multi-frequency composite, non-invasive focused ultrasound coronary thrombolysis system in vitro. Background technique [0002] Coronary heart disease is a kind of heart disease that is caused by coronary artery sclerosis or spasm, narrowing, blockage or thrombus formation to cause lumen occlusion, resulting in myocardial ischemia hypoxia or infarction. Coronary heart disease is a common disease that endangers the health of middle-aged and elderly people. Myocardial infarction is a serious clinical manifestation type of coronary heart disease. Acute myocardial infarction is acute occlusion of coronary artery, blood flow interruption, and ischemic necrosis of local myocardium caused by it. It is a clinical disease with high morbidity and high mortality. Cardiovascular diseases. Therefore, removing vascular embolism or plaque, timely recanalizing the blocke...

AI Technical Summary

Problems solved by technology

The currently widely used ultrasound equipment with a frequency of 800KHz for physiotherapy is obviously not the most ideal ultrasonic thrombolysis equipment for dissolving thrombus.

[0014] Although low-frequency ultrasound has the above-mentioned advantages, in specific applications, because its wavelength is too large (take 25KHz ultrasound as an example, the wavelength is 6cm), and according to acoustic theory, the focal spot area cannot be smaller than the wavelength by applying modern acoustic focusing technology. (That is, the focal spot of 25KHz focused ultrasound cannot be less than 6cm), therefore, the purpose of focused ultrasound therapy cannot be achieved; while high-frequency ultrasound can use focusing technology to achieve the purpose of focusing to several millimeters, but due to its significant heating effect, and May damage surrounding tissue

[0015] The extracorporeal ultrasonic thrombolysis therapy technology introduced in the current public literature uses a non-focused ultrasonic treatment head, which directly places the ultrasonic treatment head in the precordial area for treatment. The defect is that no positioning technology is used. In this state, The treatment sound intensity usually cannot be higher than 1.5W / cm 2 , otherwise it may cause myocardial damage, while 1.5W / cm 2 The sound intensity and thrombolytic effect are obviously limited. Since the treatment is not selective, the normal myocardium and the myocardium of the lesion are irradiated with the same ultrasonic power, and the normal myocardium may also be affected.

[0016] Another shortcoming of current extracorporeal ultrasound thrombolytic therapy is that there is no measure to monitor myocardial blood flow and arrhythmia during treatment, so that it is impossible to evaluate the therapeutic effect in time and reduce the occurrence of cardiovascular complications

[0017] At present, another defect of ultrasonic thrombolytic therapy in vitro is that coronary atherosclerosis is not used as a treatment indication, and the vast majority of myocardial infarction is caused by coronary atherosclerosis. Studies have shown that low-frequency ultrasound can clearly and effectively lyse Atherosclerotic plaque, reducing the stenosis of coronary artery caused by plaque, is an effective means to restore coronary blood flow, and can prevent the occurrence and development of myocardial infarction by treating atherosclerosis

Images